Immunikas aims to develop treatments for incurable autoimmune diseases caused by cell wall deficient mycobacteria transmitted through food. The company will pursue new therapeutic agents paired with diagnostics to treat infected humans and remove infections from food animals. Their initial focus is on developing drugs targeting an innate immune defect linked to many autoimmune conditions like Crohn's disease, diagnosing infections using a mycobacteria assay. Future work involves improving antibiotic regimens with more potent, long-lasting drugs.
Dr. H. Morgan Scott - Science and Practice - How does the Science of Antibiot...John Blue
Science and Practice - How does the Science of Antibiotic Resistance and Use Get Applied in Veterinary and Farming Practices? - Dr. Eric Moore, Technical Director, Norbrook, Inc., Dr. H. Morgan Scott, Professor of Epidemiology, Texas A&M; Dr. Donna Carver, Extension Specialist, Poultry Veterinarian, North Carolina State University; Dr. Joel Nerem, Pipestone Veterinary Services, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Xeraya & Allecra: The Fight Against Gram-Negative Drug-Resistant Bacteria (Hi...Kumaraguru Veerasamy
A brief overview on one of the biggest challenges in the pharmaceutical industry: 5 key gram-negative drug-resistant bacteria strains are infecting millions, and killing thousands every year across the US and Europe. Xeraya Capital, together with Allecra Therapeutics are in the fight against these resistant bacteria.
AMR & Alternative Stratergies - MicrobiologySijo A
Antibiotic resistance poses one of the most important health challenges of the 21st century.
The rise of multidrug-resistant bacteria has already led to a significant increase in human disease and death.
The U.S. Centers for Disease Control and Prevention estimates that approximately 2.8 million people worldwide are infected with antibiotic-resistant bacteria, accounting for 35,000 deaths each year in the U.S. and 700,000 deaths around the globe.
Resistance to antibiotics is one of the main important facts that most nations are working on. Actually, in USA, it is considered as a health problem to solve. Why it happens? Here is a review to answer this.
Dr. H. Morgan Scott - Science and Practice - How does the Science of Antibiot...John Blue
Science and Practice - How does the Science of Antibiotic Resistance and Use Get Applied in Veterinary and Farming Practices? - Dr. Eric Moore, Technical Director, Norbrook, Inc., Dr. H. Morgan Scott, Professor of Epidemiology, Texas A&M; Dr. Donna Carver, Extension Specialist, Poultry Veterinarian, North Carolina State University; Dr. Joel Nerem, Pipestone Veterinary Services, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Xeraya & Allecra: The Fight Against Gram-Negative Drug-Resistant Bacteria (Hi...Kumaraguru Veerasamy
A brief overview on one of the biggest challenges in the pharmaceutical industry: 5 key gram-negative drug-resistant bacteria strains are infecting millions, and killing thousands every year across the US and Europe. Xeraya Capital, together with Allecra Therapeutics are in the fight against these resistant bacteria.
AMR & Alternative Stratergies - MicrobiologySijo A
Antibiotic resistance poses one of the most important health challenges of the 21st century.
The rise of multidrug-resistant bacteria has already led to a significant increase in human disease and death.
The U.S. Centers for Disease Control and Prevention estimates that approximately 2.8 million people worldwide are infected with antibiotic-resistant bacteria, accounting for 35,000 deaths each year in the U.S. and 700,000 deaths around the globe.
Resistance to antibiotics is one of the main important facts that most nations are working on. Actually, in USA, it is considered as a health problem to solve. Why it happens? Here is a review to answer this.
Vaccines (Immunotherapy) along with COVID-19 Overview, Types of Vaccines, Adjuvants, Antigen Uptake Mechanism, COVID-19 Mechanism Of Action, and much more.
Mechanism of different types of vaccines in developmentEmilioMolina23
Recap of certain vaccines technologies against Covid-19
Introduce MOA of current and in development Covid-19 vaccines
Ever since the first vaccine was developed in 1796 to treat smallpox, several different methods have been created to develop successful vaccines. Today, those methods, known as vaccine technologies, are more advanced and use the latest technology to help protect the world from preventable diseases.
Depending on the pathogen (a bacteria or virus) that is being targeted, different vaccine technologies are used to generate an effective vaccine.
In total, there are five different vaccine technology platforms in this presentation each with its own benefits, and examples.
Synopsis
Introduction
History
Definition
Need for edible vaccine
Plants normally used for production of
edible vaccine
Production
Mode of application
Advantages
Disadvantages
Application
Conclusion
References
Biopharmaceutical Research Evolves Against
Infectious Diseases with Nearly 400 Medicines
and Vaccines in Testing.
Throughout history, infectious diseases
have taken a devastating toll on the lives
and well-being of people around the
world. Caused when pathogens such
as bacteria or viruses enter a body and
multiply, infectious diseases were the
leading cause of death in the United
States until the 1920s. Today, vaccines
and infectious disease treatments have
proven to be effective treatments in
many cases, but infectious diseases still
pose a very serious threat to patients.
1. The mission of Immunikas is to address incurable and debilitating
autoimmune conditions.
The company is based on the development of products based on the
discovery of cell wall deficient mycobacteria transmitted through our food
chain. This infection has been associated with many autoimmune
conditions. These conditions are temporarily responsive to mycobacteria
antibiotics for variable periods of time, probably due to the emergence of
resistant forms of the bacterium.
The Immunikas strategy is to pursue new therapeutic agents coupled with
companion diagnostics to diagnose and treat infected humans. These
agents may also be useful for removing infections from animals in our food
chain. Initial therapeutics will address an innate immune defect that is
considered to be responsible for a wide variety of autoimmune conditions,
which are diagnosed through a mycobacteria assay. The initial disease
focus will be Crohn's Disease. Also envisioned are future generations of
antibiotics to complement the existing antibiotic regimens. Antibiotic
assays will target drugs with both greater potency and durability than those
presently used for tuberculosis therapy.
